310 related articles for article (PubMed ID: 37418089)
21. A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
Cui Z; Cheng F; Wang L; Zou F; Pan R; Tian Y; Zhang X; She J; Zhang Y; Yang X
Front Pharmacol; 2023; 14():1259908. PubMed ID: 37954852
[No Abstract] [Full Text] [Related]
22. Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System.
Wang G; Wang J; Du R; Wang Y; Li Z
Paediatr Drugs; 2024 Mar; 26(2):175-185. PubMed ID: 38153627
[TBL] [Abstract][Full Text] [Related]
23. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
24. A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database.
Zhao B; Zhang X; Chen M; Wang Y
Expert Opin Drug Metab Toxicol; 2023; 19(6):381-387. PubMed ID: 37421631
[TBL] [Abstract][Full Text] [Related]
25. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
[TBL] [Abstract][Full Text] [Related]
26. A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system.
Liu M; Gu L; Zhang Y; Zhou H; Wang Y; Xu ZX
Front Pharmacol; 2024; 15():1290975. PubMed ID: 38357304
[No Abstract] [Full Text] [Related]
27. Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022.
Du Y; Zhu J; Guo Z; Wang Z; Wang Y; Hu M; Zhang L; Yang Y; Wang J; Huang Y; Huang P; Chen M; Chen B; Yang C
Expert Rev Clin Pharmacol; 2024; 17(2):189-201. PubMed ID: 38269492
[TBL] [Abstract][Full Text] [Related]
28. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.
Lin W; Xu J; Liao Y; Lin X; Yang J; Zhuang W
Int J Clin Pharm; 2024 Jun; 46(3):614-622. PubMed ID: 38100054
[TBL] [Abstract][Full Text] [Related]
29. Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database.
Zhu H; Qu Y; Du Z; Zhou Q; Shen Y; Jiang Y; Zhou Z; Zhou H
J Affect Disord; 2024 Feb; 347():45-50. PubMed ID: 37992768
[TBL] [Abstract][Full Text] [Related]
30. Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system.
Li Z; Zou W; Yuan J; Zhong Y; Fu Z
Expert Opin Drug Saf; 2024 Jun; 23(6):763-770. PubMed ID: 37515501
[TBL] [Abstract][Full Text] [Related]
31. Haematopoietic cytopenia associated with cyclin-dependent kinase 4/6 inhibitors: A real-world study of data from the food and drug administration adverse event reporting system database.
Ren X; Yan C; Tian L; Cui X
Int J Immunopathol Pharmacol; 2022; 36():3946320221145520. PubMed ID: 36565299
[TBL] [Abstract][Full Text] [Related]
32. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
Liu W; Du Q; Guo Z; Ye X; Liu J
Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
[No Abstract] [Full Text] [Related]
33. A pharmacovigilance study of adverse event profiles and haemorrhagic safety of bevacizumab based on the FAERS database.
Tang L; Ding C; Li H; Yin G; Zhang H; Liu WS; Ji Y; Li H
Expert Opin Drug Saf; 2024 Feb; 23(2):213-220. PubMed ID: 37581403
[TBL] [Abstract][Full Text] [Related]
34. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Yin Y; Shu Y; Zhu J; Li F; Li J
Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
[TBL] [Abstract][Full Text] [Related]
35. A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System.
Shu Y; He X; Liu Y; Wu P; Zhang Q
Clin Epidemiol; 2022; 14():789-802. PubMed ID: 35789689
[TBL] [Abstract][Full Text] [Related]
36. Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system.
Zhang Y; Jia X; Shi X; Chen Y; Xue M; Shen G; Wen L; Qiao Y; Yang Y
Gen Hosp Psychiatry; 2024 Jun; 90():22-29. PubMed ID: 38901166
[TBL] [Abstract][Full Text] [Related]
37. Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
Shu Y; Ding Y; Liu Y; Wu P; He X; Zhang Q
Front Pharmacol; 2022; 13():862508. PubMed ID: 35754494
[No Abstract] [Full Text] [Related]
38. Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study.
Cepaityte D; Siafis S; Egberts T; Leucht S; Kouvelas D; Papazisis G
Schizophr Bull; 2021 Apr; 47(3):672-681. PubMed ID: 33289848
[TBL] [Abstract][Full Text] [Related]
39. Alpelisib-Induced Diabetic Ketoacidosis: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and Review of the Literature.
Ziegengeist JL; Elmes JB; Strassels SA; Patel JN; Moore DC
Clin Breast Cancer; 2024 Jun; 24(4):e204-e209. PubMed ID: 38245400
[TBL] [Abstract][Full Text] [Related]
40. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
Gatti M; Antonazzo IC; Diemberger I; De Ponti F; Raschi E
Eur J Prev Cardiol; 2021 Aug; 28(9):983-989. PubMed ID: 34402868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
